hemoglobinuria


Also found in: Thesaurus, Medical, Legal, Encyclopedia, Wikipedia.

he·mo·glo·bi·nu·ri·a

 (hē′mə-glō′bə-no͝o′ē-ə, -nyo͝or′-)
n.
The presence of hemoglobin in the urine.

he′mo·glo′bi·nu′ric adj.

he•mo•glo•bi•nu•ri•a

(ˌhi məˌgloʊ bəˈnʊər i ə, -ˈnyʊər-)

n.
the presence of hemoglobin pigment in the urine.
[1865–70]
he`mo•glo`bi•nu′ric, adj.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.hemoglobinuria - presence of hemoglobin in the urine
symptom - (medicine) any sensation or change in bodily function that is experienced by a patient and is associated with a particular disease
Translations

hemoglobinuria

n hemoglobinuria; paroxysmal nocturnal — hemoglobinuria paroxística nocturna
References in periodicals archive ?
The proceeds of the financing will be used to initiate Phase 3 trials with APL-2 in paroxysmal nocturnal hemoglobinuria, a rare, chronic, life-threatening blood disorder, and advance development in other indications.
Although Alexion continuously maintains more than 18 months of Soliris inventory in addition to its two manufacturing sources, the need for Soliris specifically packaged for use at various centers in Germany was greater than the normal use of Soliris for patients with paroxysmal nocturnal hemoglobinuria (PNH) in that country.
M2 PHARMA-July 31, 2017-US FDA Grants Orphan Drug Designation to Ra Pharmaceuticals' RA101495 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Nasdaq: ALXN) today announced that researchers are scheduled to present data on Soliris([R]) (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation, at the 53rd Annual Meeting of the American Society of Hematology (ASH).
Soliris has been previously approved in the US (2007), European Union (2007), Japan (2010) and in other territories, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare and life-threatening blood disorder.
M2 PHARMA-June 28, 2017-Ra Pharmaceuticals Releases Initial Study Data of RA101495 in Paroxysmal Nocturnal Hemoglobinuria
Nasdaq: ALXN) today announced the presentation of research that provides further insight into the clinical consequences of paroxysmal nocturnal hemoglobinuria (PNH), and positive impact of Soliris[R] (eculizumab) therapy on long-term outcomes.
Soliris is approved in the United States, EU, Japan, and other countries for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, two ultra-rare, complement-mediated disorders.
Findings will be presented from studies of Soliris as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) as well as a potential treatment for patients with atypical hemolytic uremic syndrome (aHUS).
Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of life-transforming treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5 and Leukotriene B4, including paroxysmal nocturnal hemoglobinuria, atypical Hemolytic Uremic Syndrome, and Guillain Barre syndrome.
Nasdaq: ALXN) today announced the presentation of an analysis fromthe National Data Registry in South Korea that evaluated the association between hemolysis and mortality in patients with paroxysmal nocturnal hemoglobinuria (PNH).
for the treatment of patients with paroxysmal nocturnal hemoglobinuria, or PNH, to reduce hemolysis.